Programmed death-ligand 1 expression and overall survival in Thai patients with gastric cancer

Programmed death-ligand 1 expression and overall survival in Thai patients with gastric cancer

Abstract Programmed death-ligand 1 (PD-L1) expression has now been implicated in gastric cancer (GC). This study was conducted to determine the impact of clinicopathological characteristics on PD-L1 expression and its association with survival in GC patients receiving standard-of-care. In total, 268...

Full description

Bibliographic Details
Main Authors:	Taned Chitapanarux, Pawut Gumrai, Sarawut Kongkarnka, Komson Wannasai, Nirush Lertprasertsuke
Format:	Article
Language:	English
Published:	Nature Portfolio 2023-05-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-023-34434-y

Similar Items

Intrapulmonary mature cystic teratoma: A case report with literature review
by: Chanakrit Boonplod, et al.
Published: (2024-07-01)

Primary hepatic perivascular epithelioid cell tumor: A case report and review of literature
by: Komson Wannasai, et al.
Published: (2023-03-01)

Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma
by: Run-Cong Nie, et al.
Published: (2020-06-01)

Outcomes of pulmonary resection in non-small cell lung cancer patients older than 70 years old
by: Apichat Tantraworasin, et al.
Published: (2020-01-01)

Potential of Thai Herbal Extracts on Lung Cancer Treatment by Inducing Apoptosis and Synergizing Chemotherapy
by: Juthathip Poofery, et al.
Published: (2020-01-01)

Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
by: Xiaojun Liu, et al.
Published: (2016-11-01)

Thai Perilla frutescens fruit oil alleviates carbon tetrachloride-induced hepatotoxicities in rats
by: Narisara Paradee, et al.
Published: (2020-01-01)

Programmed death receptor-1/programmed death-ligand 1 inhibitors: Clinical progress and biomarker exploration in gastric cancer
by: Jin Shi, et al.
Published: (2024-10-01)

Preclinical medical student satisfaction of Team-based learning in Chiang Mai University
by: Komson Wannasai, et al.
Published: (2023-10-01)

Role of Computed Tomography in Predicting Programmed Death Ligand-1 Positivity in Gastric Adenocarcinoma
by: Yu ZH, et al.
Published: (2025-02-01)

Acute and subchronic oral toxicity assessment of extract from Etlingera pavieana rhizomes
by: Natthakarn Chiranthanut, et al.
Published: (2022-01-01)

Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumourigenesis
by: Lertprasertsuke Nirush, et al.
Published: (2005-10-01)

Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central Switzerland
by: Valentina Allmann, et al.
Published: (2023-01-01)

The Clinicopathological Features and Overall Survival of Patients With Gastric Neuroendocrine Carcinoma
by: Bin Xu MD, et al.
Published: (2021-11-01)

Programmed death ligand 1 (PD-L1) expression in gastric cancer: literature review
by: T. N. Sotnikova, et al.
Published: (2023-07-01)

Anti-programmed death ligand 1 (PD-L1) inhibitors in metastatic gastric cancer
by: Jang Ho Cho, et al.
Published: (2017-12-01)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
by: Wei-Bo Yu, et al.
Published: (2019-09-01)

Gastroprotective effects of Pikad Tri-phol-sa-mut-than herbal remedy on multiple gastric ulcer models in rats
by: Bing Tan, et al.
Published: (2023-08-01)

Programmed death ligand-1 protein expression difference in basal like and non-basal like triple negative breast cancer and its association with disease free survival and overall survival: A systematic review
by: Freda Halim, et al.
Published: (2021-09-01)

Novel nomogram to predict the overall survival of postoperative patients with gastric signet
by: Donghui Liu, et al.
Published: (2023-08-01)

Programmed Cell Death Ligand 1 Expression in Cytological and Surgical Non-Small Cell Lung Cancer Specimens in Association with EGFR Mutation and Overall Survival: A Single-Institution Experience
by: Elif SAYMAN GOKAL, et al.
Published: (2022-09-01)

Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections
by: Min Ye, et al.
Published: (2020-05-01)

Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes
by: Haotian Liao, et al.
Published: (2019-09-01)

Relationship between Helicobacter pylori and expression of programmed death-1 and its ligand in gastric intraepithelial neoplasia and early-stage gastric cancer
by: Shen B, et al.
Published: (2019-05-01)

Modelling the overall impacts of COVID-19 on the Thai economy
by: Sasatra Sudsawasd, et al.
Published: (2023-06-01)

Development and validation of a pretreatment nomogram to predict overall survival in gastric cancer
by: Etsuro Bando, et al.
Published: (2020-08-01)

Identification of an EMT-Related Gene Signature for Predicting Overall Survival in Gastric Cancer
by: Weiyu Dai, et al.
Published: (2021-06-01)

Transplantable programmed death ligand 1 expressing gastroids from gastric cancer prone Nfkb1 −/− mice
by: Jun T. Low, et al.
Published: (2021-11-01)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
by: Otgontuya Ganbaatar, et al.
Published: (2021-12-01)

Random survival forest in determination of important risk factors on overall survival and disease-free survival in gastric cancer patients
by: M. Safari, et al.
Published: (2023-07-01)

Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinoma
by: Jhe-Cyuan Guo, et al.
Published: (2019-01-01)

Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials
by: Linyan Zeng, et al.
Published: (2022-04-01)

Association of disease activity with programmed cell death 1 and its ligand programmed cell death ligand 1 expressions in lupus patients
by: Eman Eissa, et al.
Published: (2022-01-01)

Evaluation of the TXNIP gene expression in gastric adenocarcinoma and its relationship with overall survival of patients
by: Zahra Shahsavar Haghighi, et al.
Published: (2023-06-01)

Increased microRNA-630 expression in gastric cancer is associated with poor overall survival.
by: Dake Chu, et al.
Published: (2014-01-01)

Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab
by: Biagio Ricciuti, MD, PhD, et al.
Published: (2024-09-01)

Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites
by: Nam-Hui Yim, et al.
Published: (2020-04-01)

Regulation of Neuroinflammation through Programmed Death-1/Programmed Death Ligand Signaling in Neurological Disorders
by: Shangfeng eZhao, et al.
Published: (2014-09-01)

Expression of programmed death-ligand 1 and programmed death-1 in patients with extramammary paget's disease
by: Hiroyuki Goto, et al.
Published: (2021-01-01)

Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
by: Jaafar Jaafar, et al.
Published: (2018-05-01)